Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features.

Authors :: Wechalekar MD
Zhao LP
Kutyna MM
Hong LE
Li J
Hung K
Scott HS
Brown A
Hahn CC
Kassahn K
Ladon D
Yeung DT
Thomas D
Patnaik M
Proudman S
Ades L
Shah MV
Kok CH
Hiwase DK
Source :: Blood cancer journal [Blood Cancer J] 2024 Jul 19; Vol. 14 (1), pp. 116. Date of Electronic Publication: 2024 Jul 19.
Publication Year :: 2024

Subjects :: Humans
Female
Male
Middle Aged
Aged
Rheumatic Diseases drug therapy
Adult
Antirheumatic Agents therapeutic use
Antirheumatic Agents adverse effects
Methotrexate therapeutic use
Methotrexate adverse effects
Autoimmune Diseases drug therapy
Autoimmune Diseases chemically induced

Full Text Access

Tools